Phase 2 clinical data published with anti-ErbB3 mAbs evaluated in lung, ovarian, and breast cancer have suggested that NRG1 expression levels may be a potential biomarker to enrich for patients who will respond to therapy [8,18,40,42]. This evidence concerns the gene ERBB3 and breast cancer.